Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
Introduction. BRAF kinase inhibitors such as Vemurafenib have shown improvement in overall survival, progression-free survival, and response rates in patients with metastatic melanoma with BRAF V600K mutation. However, there were no cases of complete remission reported in patients with V600K mutatio...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2016/2672671 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566863182168064 |
|---|---|
| author | K. Sahadudheen Md. Rafiqul Islam M. Iddawela |
| author_facet | K. Sahadudheen Md. Rafiqul Islam M. Iddawela |
| author_sort | K. Sahadudheen |
| collection | DOAJ |
| description | Introduction. BRAF kinase inhibitors such as Vemurafenib have shown improvement in overall survival, progression-free survival, and response rates in patients with metastatic melanoma with BRAF V600K mutation. However, there were no cases of complete remission reported in patients with V600K mutation before. Case Presentation. A 53-year-old man with metastatic melanoma and dialysis dependent end stage renal failure was treated safely with Vemurafenib for a BRAF V600K mutation positive melanoma and the case was reported elsewhere. After a long follow-up of the same patient treated with Vemurafenib, a complete radiological response was observed and the renal functions remained stable throughout the treatment. Main toxicities reported were grade 1 photosensitivity and skin cancers. Vemurafenib was discontinued but patient remains disease free 12 months after stopping treatment and the clinical review is ongoing. Conclusion. This is the first reported case of complete radiological response to a BRAF inhibitor in metastatic melanoma with BRAF V600K mutation and remains disease free even after discontinuation of treatment. This also shows clinical safety of Vemurafenib in end stage renal failure and highlights the need for closer look at the subgroup of patients with BRAF V600K mutation and its tumour biology. |
| format | Article |
| id | doaj-art-eb99e462021346ac9a8094e38040442f |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-eb99e462021346ac9a8094e38040442f2025-02-03T01:03:08ZengWileyCase Reports in Oncological Medicine2090-67062090-67142016-01-01201610.1155/2016/26726712672671Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K MutationK. Sahadudheen0Md. Rafiqul Islam1M. Iddawela2Department of Oncology, Goulburn Valley Health, Graham Street, Shepparton, VIC 3630, AustraliaResearch Unit, Goulburn Valley Health, Shepparton, VIC 3630, AustraliaDepartment of Oncology, Goulburn Valley Health, Graham Street, Shepparton, VIC 3630, AustraliaIntroduction. BRAF kinase inhibitors such as Vemurafenib have shown improvement in overall survival, progression-free survival, and response rates in patients with metastatic melanoma with BRAF V600K mutation. However, there were no cases of complete remission reported in patients with V600K mutation before. Case Presentation. A 53-year-old man with metastatic melanoma and dialysis dependent end stage renal failure was treated safely with Vemurafenib for a BRAF V600K mutation positive melanoma and the case was reported elsewhere. After a long follow-up of the same patient treated with Vemurafenib, a complete radiological response was observed and the renal functions remained stable throughout the treatment. Main toxicities reported were grade 1 photosensitivity and skin cancers. Vemurafenib was discontinued but patient remains disease free 12 months after stopping treatment and the clinical review is ongoing. Conclusion. This is the first reported case of complete radiological response to a BRAF inhibitor in metastatic melanoma with BRAF V600K mutation and remains disease free even after discontinuation of treatment. This also shows clinical safety of Vemurafenib in end stage renal failure and highlights the need for closer look at the subgroup of patients with BRAF V600K mutation and its tumour biology.http://dx.doi.org/10.1155/2016/2672671 |
| spellingShingle | K. Sahadudheen Md. Rafiqul Islam M. Iddawela Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation Case Reports in Oncological Medicine |
| title | Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation |
| title_full | Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation |
| title_fullStr | Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation |
| title_full_unstemmed | Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation |
| title_short | Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation |
| title_sort | long term survival and continued complete response of vemurafenib in a metastatic melanoma patient with braf v600k mutation |
| url | http://dx.doi.org/10.1155/2016/2672671 |
| work_keys_str_mv | AT ksahadudheen longtermsurvivalandcontinuedcompleteresponseofvemurafenibinametastaticmelanomapatientwithbrafv600kmutation AT mdrafiqulislam longtermsurvivalandcontinuedcompleteresponseofvemurafenibinametastaticmelanomapatientwithbrafv600kmutation AT middawela longtermsurvivalandcontinuedcompleteresponseofvemurafenibinametastaticmelanomapatientwithbrafv600kmutation |